Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD73, and methods of use thereof.

Abstract: The present disclosure provides a linear motor including: a housing body with a containment space; a vibrator assembly suspended in the containment space by an elastic member for vibrating along a vibration direction; a stator assembly fixedly connected to the housing body and having a magnetic axis along the vibration direction; and two magnets located on both sides of the magnetic axis and spaced from the stator assembly, including a first magnet section and a second magnet section located on both sides of the first magnet section. A magnetic field strength of the first magnet section along the magnetic axis is greater than a magnetic field strength of the second magnet section along the magnetic axis. The configuration of the invention can effectively reduce the static attraction force of the magnetic circuit, and increase the overall rigidity of the linear motor.

Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD28, and methods of use thereof.

Abstract: A fiber silica composite microsphere for a shale stratum comprises a hollow silica sphere and fibers, and the fibers are partially coated on an outer surface of the hollow silica sphere and partially embedded into an interior of the hollow silica sphere. The hollow silica sphere has an outer diameter of 1-5 ?m and an inner diameter of 0.8-4.7 ?m; the fibers have a length of 5-10 ?m and a width of 1-3 ?m.

Abstract: Disclosed are processes for preparing hybrid perovskite quantum dots and the resulting hybrid perovskite quantum dots and uses thereof. Such quantum dots are useful as semiconductors in devices such as solar cells and light-emitting diodes.

Abstract: Non-human animals, methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanized programmed death-ligand 1 (PD-L1, PDL1, or B7-H1). Such non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous PD-L1 gene so that the non-human animals express a humanized PD-L1 protein that includes a human portion and an endogenous portion (e.g., a non-human portion).

Abstract: A droop reduction circuit on a die includes a voltage detector circuit to detect voltage droop in a supply voltage received by a first load. The droop reduction circuit further includes a driver controller circuit to drive power switch (PSH) banks in response to detection of the voltage droop. Each of the PSH banks includes at least one power switch having an input terminal, a gate terminal, and an output terminal. The input terminal is to receive a secondary voltage, which is higher than the supply voltage and is also received by a second load on the die. The gate terminal is to receive a drive signal from the driver controller, and the output terminal is to pull up the voltage droop in the supply voltage.

Abstract: A method for preparing a NdFeB permanent magnetic material may include providing a covered NdFeB magnetic powder by depositing heavy rare earth particles or high-melting particles onto a NdFeB magnetic powder by physical vapor deposition; and performing orientation molding and sintering on the covered NdFeB magnetic powder to provide the NdFeB permanent magnetic material.

Abstract: The present disclosure relates to the genetically modified non-human animals that express a human or chimeric OX40, and methods of use thereof.

Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) programmed cell death protein 1 (PD-1), and methods of use thereof. In one aspect, the animals have an insertion of a sequence encoding a human or humanized programmed cell death protein 1 (PD-1) at an endogenous PD-1 gene locus. This animal model can express a PD-1 protein containing a functional domain of the human PD-1 protein, and can be used as an animal model for developing therapeutics for human diseases and disorders, and assessing the toxicity and/or the efficacy of these human therapeutics.

Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD137, and methods of use thereof.

Abstract: The present document provides image processing methods and apparatus. One claim recites: obtaining a signal to be encoded in color image data, the signal comprising a plural-bit payload; predicting a resulting color of overprinting several inks on a substrate, the overprinting representing the color image data encoded with the signal; using the resulting color for both i) visibility evaluation of the overprinting, and ii) signal robustness evaluation of the overprinting as seen by an imaging device. Other claims and combinations are provided.

Abstract: This disclosure relates to advanced signal processing technology including steganographic embedding and digital watermarking.

Abstract: This disclosure relates to advanced signal processing technology including signal encoding and digital watermarking. Image areas are selected in an encoded digital design, and corresponding areas from a printed version of the encoded digital design are evaluated to determined signal robustness after printing.

Abstract: The present disclosure relates to the genetically modified non-human animals that express a human or chimeric (e.g., humanized) T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), and methods of use thereof.

Abstract: Provided is a method for preparing a PD-1 gene-modified humanized animal model. The method utilizes the CRIPSR/Cas9 technique to replace partial fragments of a mouse PD-1 gene with fragments of a human PD-1 gene using homologous recombination by constructing a targeting vector, thereby preparing a gene-modified humanized mouse. This mouse can normally express a PD-1 protein containing the functional domain of the human PD-1 protein, and can be used as an animal model for mechanism research regarding PD-1, PD-L1 and other signals, for screening regulators, and for toxicological research. The method has an important and high application value in studies on functions of the PD-1 gene and in the development of new drugs.

Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL15, and methods of use thereof.

Abstract: A vehicle interior component configured to provide an illuminated display/image and comprising a composite structure is disclosed. The component may comprise a cover providing a surface for the illuminated display/image and a substrate; the cover may comprise a cover layer, bottom layer and/or intermediate layer. The cover layer may comprise a surface layer and a base layer. The base layer and/or bottom layer may comprise a reinforcing layer. The surface layer, cover layer and/or base layer may comprise a pigment. The surface layer, cover layer and/or bottom layer may comprise a colorant (or pigment, dye, etc.). The bottom layer may comprise a pattern region comprising the image, a mask and/or light-blocking layer. The composite structure may comprise the cover, a functional layer, spacer/buffer layer, diffuser layer, sensor grid, capacitive sensor, textile and/or base/substrate. The cover surface may comprise a skin.

Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL6R and/or IL6, and methods of use thereof.

Abstract: The present invention relates to a drilling fluid for enhancing stratum pressure bearing capacity, and a method of preparing and using the drilling fluid. The drilling fluid comprises water, bentonite, low adhesive aggregation anionic cellulose, lignite resin, high temperature resistant and salt resistant filtrate reducer, silanol inhibitor, inorganic micrometer-nanometer rigid particles and emulsified asphalt. The bentonite is 2-9 parts by weight, the low adhesive aggregation anionic cellulose is 0.1-1 parts by weight, the lignite resin is 1-5 parts by weight, the high temperature resistant and salt resistant filtrate reducer is 0.1-2 parts by weight, the silanol inhibitor is 0.1-2 parts by weight, the inorganic micrometer-nanometer rigid particles are 0.5-5 parts by weight, and the emulsified asphalt is 1-10 parts by weight, based on 100 parts by weight of water.